These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Antisense oligonucleotide technology in the development of cancer therapeutics. Tseng BY; Brown KD Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240 [No Abstract] [Full Text] [Related]
27. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Mirabelli CK; Bennett CF; Anderson K; Crooke ST Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361 [TBL] [Abstract][Full Text] [Related]
28. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential. Olie RA; Zangemeister-Wittke U Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155 [TBL] [Abstract][Full Text] [Related]
29. Antisense technology and prospects for therapy of viral infections and cancer. Wagner RW; Flanagan WM Mol Med Today; 1997 Jan; 3(1):31-8. PubMed ID: 9021740 [TBL] [Abstract][Full Text] [Related]
31. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications. Gewirtz AM Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543 [TBL] [Abstract][Full Text] [Related]
32. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Kim R; Emi M; Matsuura K; Tanabe K Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564 [TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cucco C; Calabretta B Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118 [TBL] [Abstract][Full Text] [Related]
34. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents. Brysch W; Schlingensiepen KH Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513 [TBL] [Abstract][Full Text] [Related]
35. Antisense therapy in malignant diseases: status quo and quo vadis? Tamm I Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947 [TBL] [Abstract][Full Text] [Related]
36. Antisense oligonucleotides as therapeutic agents. Alama A; Barbieri F; Cagnoli M; Schettini G Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660 [TBL] [Abstract][Full Text] [Related]